Incyte Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Incyte şirketinin toplam hissedar öz sermayesi $4.2B ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $5.8B ve $1.7B dir. Incyte 'in FAVÖK'ü $966.5M faiz karşılama oranı -11.2 dur. Şirketin $2.4B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	-11.2x
Nakit	US$2.42b
Eşitlik	US$4.17b
Toplam yükümlülükler	US$1.65b
Toplam varlıklar	US$5.82b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Incyte Corporation's (NASDAQ:INCY) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Aug 14

Additional Considerations Required While Assessing Incyte's (NASDAQ:INCY) Strong Earnings

Aug 06

Tactical Expansions And First-in-Class Molecules Set To Propel Growth In High-Need Medical Areas

Aug 22 Incyte's focus on expanding its clinical pipeline with first-in-class molecules and novel therapies aims to drive growth by increasing market share and revenue.

Incyte: Monjuvi Advancement Continues With Positive FL Treatment Data

Aug 19

Incyte: The Worst Has Been Avoided

Jun 16

Incyte Pharmaceuticals: Cheap Enough Now (Rating Upgrade)

Apr 26

Incyte: A Potential GARP Superstar

Feb 27

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: INCY 'nin kısa vadeli varlıkları ( $3.6B ) kısa vadeli yükümlülüklerini ( $1.3B ) aşıyor.

Uzun Vadeli Yükümlülükler: INCY şirketinin kısa vadeli varlıkları ( $3.6B ) uzun vadeli yükümlülüklerini ( $371.8M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: INCY borçsuzdur.

Borcun Azaltılması: INCY şirketinin 5 yıl önce borç/öz sermaye oranı 0.8% iken borcu yok.

Borç Kapsamı: INCY un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: INCY şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.

Bilanço

Sağlıklı şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/10/03 22:23
Gün Sonu Hisse Fiyatı	2025/10/03 00:00
Kazançlar	2025/06/30
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Incyte Corporation 57 Bu analistlerden 20, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Jasper Hellweg	Argus Research Company
Thomas Russo	Baird
Ishan Majumdar	Baptista Research

Incyte Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Incyte Corporation Appoints Thomas Tray as Principal Financial Officer, Effective as of September 16, 2025

Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer, Effective September 22, 2025

Incyte Announces Additional FDA Approval of Opzelura®? (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis

Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025

Incyte Launches HS TRUTHS to Spotlight the True Lived Experience of Hidradenitis Suppurativa

Incyte Announces Executive Changes, Effective August 25, 2025

Incyte Corporation's (NASDAQ:INCY) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Actuate Therapeutics, Inc. to Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer

Price target increased by 7.2% to US$80.83

Additional Considerations Required While Assessing Incyte's (NASDAQ:INCY) Strong Earnings

Incyte Corporation Announces Departure of Christiana Stamoulis as Executive Vice President, Effective September 16, 2025

Consensus EPS estimates increase by 18%

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Incyte Corporation Raises Revenue Guidance for the Fiscal Year 2025

Executive VP & Chief Medical Officer recently sold US$1.0m worth of stock

Incyte Corporation to Report Q2, 2025 Results on Jul 29, 2025

Insider recently sold US$743k worth of stock

Incyte: New CEO Brings A New Possible Outcome

Incyte Corporation Announces Chief Executive Officer Changes

Incyte Announces Update on FDA Review of Ruxolitinib Cream (Opzelura) for Children Ages 2-11 with Atopic Dermatitis

Incyte Announces FDA Approval of Monjuvi®? in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

Incyte Announces Phase 3 Data for it's Retifanlimab (Zynyz®?) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet

Incyte Corporation Announces FDA Approval of Zynyz (Retifanlimab-Llwr) Making It the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States

Incyte Corporation, Annual General Meeting, Jun 10, 2025

Investors Aren't Buying Incyte Corporation's (NASDAQ:INCY) Revenues

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Incyte Corporation Revises Revenue Guidance for the Year 2025

Incyte Corporation to Report Q1, 2025 Results on Apr 29, 2025

Insider recently sold US$1.3m worth of stock

Incyte: Still A 'Buy' Despite HS Treatment Data With Povorcitinib

Lilly's baricitinib Delivered High Rates of Hair Regrowth for Adolescents with Severe Alopecia Areata in Phase 3 BRAVE-AA-PEDS Study

Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% in Patients with Prurigo Nodularis at 2025 American Academy of Dermatology Annual Meeting

Incyte: Q4 Earnings Outlines Multiple Drug Launches In 2025

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Executive VP & Chief Medical Officer recently sold US$898k worth of stock

Incyte Corporation to Report Q4, 2024 Results on Feb 10, 2025

Incyte and Syndax Pharmaceuticals Announce U.S. Food and Drug Administration Approval of Niktimvo (axatilimab-csfr) 9 mg and 22 mg Vial Sizes

Incyte Corporation Announces Retirement of Barry P. Flannelly as Executive Vice President, Effective July 31, 2025

Incyte: Multiple Drug Launches Bode Well For Future Growth

Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer

Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs

Incyte: Q3 Earnings Ramping Up Growth To Jump The Patent Cliff

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 13%

Consensus EPS estimates fall by 15%

Incyte Corporation to Report Q3, 2024 Results on Oct 29, 2024

Consensus EPS estimates fall by 13%

Insufficient new directors

Incyte 's Cdk2 Inhibitor Incb123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer

Tactical Expansions And First-in-Class Molecules Set To Propel Growth In High-Need Medical Areas

Incyte: Monjuvi Advancement Continues With Positive FL Treatment Data

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma

Executive VP & Chief Medical Officer recently sold US$704k worth of stock

Incyte and Syndax Pharmaceuticals Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)

Executive VP & Chief Medical Officer notifies of intention to sell stock

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Executive VP of Global Medical Affairs recently sold US$1.1m worth of stock

Consensus EPS estimates fall by 74%

Executive VP of Global Medical Affairs notifies of intention to sell stock

Incyte Corporation to Report Q2, 2024 Results on Jul 30, 2024

Incyte: The Worst Has Been Avoided

Executive VP & GM of North America recently sold US$1.1m worth of stock

Executive VP & GM of North America notifies of intention to sell stock

Incyte Corporation (NasdaqGS:INCY) acquired Escient Pharmaceuticals, Inc. from a group of shareholders.

Incyte Corporation (NasdaqGS:INCY) announces an Equity Buyback for $1,672 million worth of its shares.

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Incyte Corporation, Annual General Meeting, Jun 12, 2024

Incyte Corporation Maintains Earnings Guidance for 2024

Incyte Pharmaceuticals: Cheap Enough Now (Rating Upgrade)

Incyte Corporation (NasdaqGS:INCY) entered into a definitive agreement to acquire Escient Pharmaceuticals, Inc. from a group of shareholders for $750 million.

Incyte Corporation to Report Q1, 2024 Results on Apr 30, 2024

Incyte Announces New Results from A Phase 2 Study Evaluating the Efficacy and Safety of Twice-Daily Ruxolitinib Cream 1.5% (Opzelura®) in Adult Patients with Hurley Stage 1 or 2 (Mild-To-Moderate) Hidradenitis Suppurativa (HS)

Incyte: A Potential GARP Superstar

Incyte Corporation Provides Earnings Guidance for 2024

Full year 2023 earnings: Revenues and EPS in line with analyst expectations